RAPP
USDRapport Therapeutics Inc. Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$26.440
Máximo
$26.440
Mínimo
$24.600
Volume
0.24M
Fundamentos da empresa
Capitalização de mercado
1.2B
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
0.80M
Bolsa de valores
NGM
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
Rapport Therapeutics, Inc. (RAPP) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript
Truist Securities Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $44
Truist Securities analyst Joon Lee initiates coverage on Rapport Therapeutics with a Buy rating and announces Price Target of $44.
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small
Rapport Announces Pricing of Public Offering of Common Stock
BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small
Rapport Announces Proposed Public Offering of Common Stock
BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small
HC Wainwright & Co. Maintains Buy on Rapport Therapeutics, Raises Price Target to $34
HC Wainwright & Co. analyst Douglas Tsao maintains Rapport Therapeutics with a Buy and raises the price target from $31 to $34.
Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving seizure freedom for
Ações relacionadas
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.